Skip to main content

Sofosbuvir / Velpatasvir / Voxilaprevir Dosage

Medically reviewed by Last updated on Jun 27, 2023.

Applies to the following strengths: 400 mg-100 mg-100 mg

Usual Adult Dose for Chronic Hepatitis C

1 tablet orally once a day for 12 weeks


  • This drug showed no additional benefit over sofosbuvir-velpatasvir in patients with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without a nonstructural protein 5A (NS5A) inhibitor.

Uses: For the treatment of patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have:
  • Genotype 1, 2, 3, 4, 5, or 6 infection and were previously treated with an NS5A inhibitor-containing HCV regimen; in clinical trials, prior NS5A inhibitor experience included daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir
  • Genotype 1a or 3 infection and were previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor; in clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon alfa/ribavirin, ribavirin, HCV NS3/4A protease inhibitor (boceprevir, simeprevir, or telaprevir)

Renal Dose Adjustments

Mild, moderate, or severe renal dysfunction: No adjustment recommended.

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): No adjustment recommended.
Moderate or severe liver dysfunction (Child-Pugh B or C): Not recommended.


  • Safety and efficacy have not been established in HCV-infected patients with moderate or severe liver dysfunction; higher voxilaprevir exposures observed in non-HCV-infected subjects.



  • RISK OF HBV REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: All patients should be tested for evidence of current/prior HBV infection before starting this drug. HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. HCV/HBV-coinfected patients should be monitored for hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.

Coadministration with rifampin

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


ESRD requiring dialysis: No adjustment recommended.

Other Comments

Administration advice:

  • Before starting this drug, test all patients for evidence of current/prior HBV infection; measure hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).
  • Administer with food.
  • Administer this drug at least 4 hours before or 4 hours after aluminum- or magnesium-containing antacids.

Storage requirements:
  • Store below 30C (86F) in the original container.

  • Each fixed-dose combination tablet contains sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg.

  • General: For clinical and laboratory signs of hepatitis flare or HBV reactivation in patients with serological proof of HBV infection (during HCV therapy with this drug and during posttreatment follow-up)
  • Hepatic: Hepatic laboratory testing in patients with compensated cirrhosis or proof of advanced liver disease (as clinically indicated); for signs/symptoms of hepatic decompensation

Patient advice:
  • Read the US FDA-approved patient labeling (Patient Information).
  • Seek medical evaluation at once for symptoms of worsening liver problems (e.g., tiredness, yellowing of the skin/white part of the eyes, bleeding/bruising more easily than normal, confusion, loss of appetite, diarrhea, dark/brown urine, dark/bloody stool, swelling of the stomach area [abdomen]/pain in the upper right side of the stomach area, sleepiness, vomiting of blood).
  • Avoid missing doses and complete the entire course of therapy.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.